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The 2019 Advancing American Kidney Health Initiative has called for a substantial 
increase in pre-emptive kidney transplantation, with the objective that 80% of those with incident 
end-stage kidney disease (ESKD) in the United States (US) be treated with a transplant or 
home-based dialysis by 2025.(1) A fundamental barrier to achieving such an ambitious goal is 
the uniquely high cost of healthcare in the US, a burden that impedes many younger and lower-
income individuals with chronic kidney disease (CKD) from early detection and timely 
nephrology care. However, even if US health policy evolves to provide truly universal healthcare 
coverage, the nephrology community must remain vigilant about identifying and mitigating many 
other pervasive factors that prevent our most vulnerable patients from receiving the optimal 
treatments for ESKD. 
In this issue of the Clinical Journal of the American Society of Nephrology, Pruthi and 
colleagues (2) assessed patient and treatment center-related barriers to kidney transplantation 
in the United Kingdom (UK). Like the US, there are challenges facing kidney transplantation in 
the UK, with the number of patients on the kidney transplant waiting list exceeding the supply of 
donor organs.(3) However, unlike the US, the UK provides universal healthcare access. The 
National Health Service (NHS) was established in the UK in 1948 with the overriding principles 
that it is free at the point of need and treatment is based on clinical need and not an individual’s 
ability to pay. In the UK, transplant recipients are covered for lifelong immunosuppressive 
therapy, and there are no differences in physician financial reimbursements associated with 
ESKD treatment modality. The UK also provides reimbursement for living donor lost wages, 
travel expenses, dependent care, and other non-medical costs related to organ donation. 
Therefore, the UK has avoided many of the barriers to kidney transplantation that exist in the 
US, not only by minimizing the costs to patients and donors but also by eliminating financial 
disincentives for physicians to refer dialysis patients for transplant.(4) However, there is 
evidence of substantial variability in transplant wait-listing practices between centers in the UK, 
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(5) and racial and ethnic minority transplant candidates have lower rates of living donor 
transplant and longer waiting times to transplant compared to white candidates.(3) 
To examine potential determinants of transplant inequity in the UK, Pruthi and 
colleagues (2) analyzed data from the Access to Transplantation and Transplant Outcome 
Measures (ATTOM) study, a prospective, national cohort study that recruited 4885 adults age 
18-75 with incident ESKD across the UK between November 1, 2011 and March 31, 2013. 
Among 2676 individuals with incident ESKD (treated with dialysis or transplant), the authors 
examined whether patient and center-related factors were associated with differences in pre-
emptive wait-listing for kidney transplantation. Among 1970 individuals who initiated dialysis 
without pre-emptive wait-listing, the authors also examined associations between patient and 
center-level factors and the outcome of being wait-listed within the first two years of starting 
dialysis.   
Approximately 26% of the UK cohort with ESKD was either pre-emptively wait-listed or 
transplanted. Consistent with findings in the US,(6) Pruthi and colleagues found that UK patients 
who were racial minorities were far less likely to be pre-emptively wait-listed than patients who 
were white. However, these differences in wait-listing were attenuated or even reversed in the 
case of Asian patients after starting dialysis. In the US, racial disparities in pre-emptive 
transplant may be partially explained by differences in access to private insurance coverage.(6) 
In the UK, where healthcare coverage is universal, these findings speak to the many other 
reasons that could also underly racial disparities in kidney transplant access, including 
differences in the availability of living donors,(3) and cultural or systematic barriers that prevent 
access to, or engagement with the healthcare system.  
Shorter durations of nephrology care were also associated with lower odds of pre-
emptive listing in the study by Pruthi and colleagues,(2) a finding that may reflect both the 
importance of early referral to nephrology care and the rate of CKD progression in determining 
access to pre-emptive transplant. For example, 54% of patients in the ATTOM cohort who had 
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polycystic kidney disease as their cause of ESKD were pre-emptively listed, compared to 16% 
of patients with diabetes. Several prior studies have also found that some racial and ethnic 
minority groups are at higher risk of rapid CKD progression than whites, even in settings with 
equal access to healthcare. In a study of US Veterans who received healthcare coverage 
through the US Department of Veterans Affairs, although black and Hispanic patients with CKD 
were more likely to receive nephrology care than their white counterparts, they were also more 
likely to experience CKD progression.(7) These findings underscore the need to test strategies, 
such as expedited transplant workup or earlier transplant referral, to improve access to pre-
emptive transplant for those who are at higher risk of rapid disease progression or more likely to 
require detailed testing. 
The study by Pruthi and colleagues (2) also suggests that although the financial burdens 
of kidney transplantation are attenuated by universal healthcare, financial insecurity is a 
pervasive barrier to kidney transplantation. The authors found that being unemployed was 
associated with a 50% lower odds of being pre-emptively waitlisted than being employed, 
whereas home and car ownership were associated with nearly double the odds of pre-emptive 
wait-listing compared to home rental and lack of car, respectively. These findings align with the 
evidence that crowd-funding efforts to mitigate patient and caregiver costs related to transplant 
are increasing, including in countries with universal healthcare coverage.(8) Further, although 
car ownership may simply be a surrogate for socioeconomic status, lack of transportation might 
also hinder patients’ abilities to travel to clinic appointments or to complete a transplant workup 
in a timely manner. In a 2010 US study, Axelrod and colleagues found that living farther from a 
transplant center was associated with reduced access to transplant, whereas having a greater 
ability to travel to more than one donation service area for transplant wait-listing was associated 
with a near doubling in the rate of transplant.(9) In light of these findings, transplant programs 
could consider implementing strategies such as satellite clinic sites or telehealth evaluations to 
ease the burden of travel before kidney transplantation.  
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In addition to the insights about patient-related barriers to transplantation, some of the 
most important knowledge to be gained from the study by Pruthi and colleagues (2) comes from 
their rigorous examination of center-level variables that might influence access to transplant. 
They found that patients who received care at kidney centers with more than 6 nephrologists, 
where transplant was discussed with all patients, and where transplant was performed at the 
center had a higher likelihood of pre-emptive wait-listing. Further, a written wait-listing protocol 
was independently associated with a lower rate of wait-listing within two years of starting 
dialysis. These center-related factors suggest that inconsistency in systems and processes for 
determining transplant candidacy have important implications for access to transplantation. For 
example, centers with fewer nephrologists per patient might have less capacity to engage 
patients in discussions about transplant. Centers that limit discussions about transplant to only 
those patients who are deemed to be the best candidates and those that use inflexible wait-
listing criteria, such as strict age or body mass index cut-offs, might reduce access for many 
candidates that could derive substantial benefit from transplantation.  
One of the strengths of the study by Pruthi and colleagues (2) is that ATTOM 
investigators collected rich demographic information on study participants, enabling the authors 
of the study to examine granular measures of socioeconomic status (e.g., car and home 
ownership) and social support as potential predictors of transplant access. As such, the study 
provides insight on the many social determinants of transplant access that typically go 
unmeasured in studies of registry data. One limitation, due to the design of ATTOM, is that there 
is no information on individuals who were pre-emptively listed during the study period but did not 
start dialysis or receive a transplant. Further, as ATTOM did not recruit individuals with non-
dialysis-dependent CKD, it does not provide information about the total “denominator” of 
potentially eligible pre-emptive transplant candidates.  
The important study by Pruthi and colleagues (2) has underscored some of the 
challenges that persist in kidney transplantation even when healthcare access is universal. Of 
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course, the US remains a long way from achieving that goal. In 2016, approximately 20% of 
younger adults who initiated dialysis in states that did not expand Medicaid were uninsured,(10) 
and the number of uninsured Americans has grown larger still in more recent years. Yet, 
findings from the UK make it apparent that barriers to transplantation are not limited to the 
availability of healthcare coverage. This knowledge should motivate the nephrology community 
to examine the equity implications of our processes to educate, evaluate and select kidney 
transplant candidates.  Although only health policy can ensure that the door to kidney 
transplantation is open for all patients who could benefit, equity in transplantation will only be 
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